达格列净对射血分数降低心衰代谢组学影响:DEFINE-HF研究
DEFINE-HF试验的靶向代谢组学分析纳入234例HFrEF患者,在随机化和12周时检测63种代谢物。达格列净较安慰剂改变酮体相关及短链/中链酰基肉碱代谢簇,但酮症少见且仅为生理水平;长链酰基肉碱等代谢簇升高与生活质量下降和NT-proBNP升高相关。
要点
- 达格列净可改变HFrEF患者酮体及脂肪酸代谢通路。
- 达格列净仅引起生理性酮症,未观察到超生理水平。
- 部分代谢物簇变化与心衰不良结局相关,与治疗分组无关。
核心结论
- 达格列净对HFrEF关键代谢通路有影响,支持酮体和脂肪酸生物学改变的作用。
- 仅观察到生理水平的酮症,未出现超生理水平酮体。
- 多种代谢生物标志物与HFrEF不良结局相关。
研究设计与样本
- DEFINE-HF为安慰剂对照试验,本分析纳入234例有靶向代谢组学数据的HFrEF患者。
- 采用靶向质谱检测随机化时和12周血浆中63种代谢物(45种酰基肉碱、15种氨基酸、3种常规代谢物)。
- 使用混合模型分析主成分分析定义的代谢物簇,并校正相关临床协变量。
- 统计显著性定义为名义P<0.05且错误发现率校正P<0.10。
主要发现
- 达格列净较安慰剂增加酮体相关、短链酰基肉碱和中链酰基肉碱主成分分析定义的代谢簇(名义P=0.01,错误发现率校正P=0.08)。
- 酮症(β-羟丁酸水平>500 μmol/L)少见:达格列净组3例(2.5%),安慰剂组1例(0.9%),未观察到超生理水平。
- 长链酰基肉碱、长链二羧酰基肉碱和芳香族氨基酸代谢簇升高与KCCQ评分下降(生活质量更差)和NT-proBNP升高相关,无治疗分组交互作用。
- 参与者平均年龄62.0±11.1岁,25%为女性,38%为黑人,平均射血分数27±8%。
关键数值与推荐
- 代谢物簇变化显著性标准:名义P<0.05且错误发现率校正P<0.10。
- 酮症定义:β-羟丁酸水平>500 μmol/L。
- 达格列净组酮症发生率2.5%(3例),安慰剂组0.9%(1例)。
临床怎么用
- 达格列净在HFrEF中的获益可能部分通过酮体和脂肪酸代谢通路改变介导。
- 临床使用达格列净时无需担忧超生理水平酮症,但仍需关注生理性酮症。
- 长链酰基肉碱等代谢物簇或可作为HFrEF不良结局的潜在生物标志物。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sodium-glucose cotransporter-2 inhibitors are foundational therapy in patients with heart failure with reduced ejection fraction (HFrEF), but underlying mechanisms of benefit are not well defined. We sought to investigate the relationships between sodium-glucose cotransporter-2 inhibitor treatment, changes in metabolic pathways, and outcomes using targeted metabolomics. METHODS: DEFINE-HF (Dapagliflozin Effects on Biomarkers, Symptoms and Functional Status in Patients With HF With Reduced Ejection Fraction) was a placebo-controlled trial of dapagliflozin in HFrEF. We performed targeted mass spectrometry profiling of 63 metabolites (45 acylcarnitines [markers of fatty acid oxidation], 15 amino acids, and 3 conventional metabolites) in plasma samples at randomization and 12 weeks. Using mixed models, we identified principal components analysis-defined metabolite clusters that changed differentially with treatment and examined the relationship between change in metabolite clusters and change in Kansas City Cardiomyopathy Questionnaire scores and NT-proBNP (N-terminal probrain natriuretic peptide). Models were adjusted for relevant clinical covariates and nominal P<0.05 with false discovery rate-adjusted P<0.10 was used to determine statistical significance. RESULTS: Among the 234 DEFINE-HF participants with targeted metabolomic data, the mean age was 62.0±11.1 years, 25% were women, 38% were Black, and mean ejection fraction was 27±8%. Dapagliflozin increased ketone-related and short-chain acylcarnitine as well as medium-chain acylcarnitine principal components analysis-defined metabolite clusters compared with placebo (nominal P=0.01, false discovery rate-adjusted P=0.08 for both clusters). However, ketosis (β-hydroxybutyrate levels >500 μmol/L) was achieved infrequently (3 [2.5%] in dapagliflozin arm versus 1 [0.9%] in placebo arm) and supraphysiologic levels were not observed. Increases in long-chain acylcarnitine, long-chain dicarboxylacylcarnitine, and aromatic amino acid metabolite clusters were associated with decreases in Kansas City Cardiomyopathy Questionnaire scores (ie, worse quality of life) and increases in NT-proBNP levels, without interaction by treatment group. CONCLUSIONS: In this study of targeted metabolomics in a placebo-controlled trial of sodium-glucose cotransporter-2 inhibitors in HFrEF, we observed effects of dapagliflozin on key metabolic pathways, supporting a role for altered ketone and fatty acid biology with sodium-glucose cotransporter-2 inhibitors in patients with HFrEF. Only physiologic levels of ketosis were observed. In addition, we identified several metabolic biomarkers associated with adverse HFrEF outcomes. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT02653482.
引用
- Selvaraj, Fu, Jones, et al. Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF. Circulation. 2022. PMID: 35603596. doi:10.1161/CIRCULATIONAHA.122.060402
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。